According to Pearl Therapeutics, a Phase 2b study has demonstrated that its PT003 glycopyrrolate/formoterol combination MDI provides superior bronchodilation compared to placebo, compared to its individual components, and compared to tiotropium. The trial involved patients with moderate to very severe COPD. Read the company’s press release.
Pearl announces positive Phase 2b results for COPD drug
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
